stockrow
Friday 6 November 2026
Export NVST’s income statement to Excel — free account
Envista Holdings Corporation
NVST Healthcare Medical Instruments & Supplies
Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024.
- Revenue
- +3.22%
- EPS
- +1,855.6%
- Free cash flow
- −6.48%
- Total debt
- −1.13%
Quarter to September 2026, against a year earlier
24.98
2.21
−8.13%
Follow NVST
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 8 | 8 | 8 |
| 1.56% | 2.21% | 3.06% | 20.52% | ||
| 0.85% | 1.23% | 1.69% | 11.26% | ||
ROIC |
4.04% | 4.36% | 5.05% | 13.61% | |
Return on Tangible Assets |
3.20% | 4.73% | 6.57% | 42.63% | |
Average Days of Receivables |
57.66 | 56.75 | 55.83 | 56.88 | |
Free Cash Flow per Share |
1.37 | 1.34 | 1.54 | 1.52 | |
Free Cash Flow |
230.90 | 220.30 | 249.00 | 244.60 | |
Capital Expenditures |
(44.80) | (51.80) | (53.60) | (57.20) | |
| Other line items | |||||
Cash ROIC |
4.00% | 3.93% | 4.42% | 4.31% | |
Accounts Receivable Turnover |
6.86 | 6.77 | 6.65 | 6.74 | |
Accounts Payable Turnover |
6.73 | 7.60 | 7.06 | 7.75 | |
Inventory Turnover |
4.66 | 4.51 | 4.46 | 4.41 | |
Average Days of Payables |
56.73 | 48.96 | 54.30 | 49.38 | |
Days of Inventory on Hand |
85.30 | 86.49 | 83.04 | 81.98 | |
Tax Rate |
(0.73) | (0.66) | (0.59) | (0.07) | |
Research and Development Expense of Revenue |
4.19% | 4.23% | 4.23% | 4.23% | |
Selling, General and Administrative Expense of Revenue |
42.53% | 42.11% | 41.43% | 41.11% | |
Share Based Compensation of Revenue |
1.38% | 1.45% | 1.42% | 1.39% | |
Interest Coverage |
5.90 | 6.90 | 7.73 | 21.38 | |
Operating CF/Net income |
5.87 | 4.02 | 3.19 | 0.48 | |
Depreciation/Fixed assets |
0.52 | 0.52 | 0.53 | 0.00 | |
Capex/Depreciation |
(0.29) | (0.33) | (0.35) | 0.00 | |
Revenue per Share |
16.19 | 17.13 | 17.64 | 17.90 | |
Operating CF per Share |
1.64 | 1.66 | 1.87 | 1.88 | |
Capex per Share |
(0.27) | (0.32) | (0.33) | (0.36) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 4 Nov 2026